Skip to main content
TrimSoMoEverything GLP-1, in one place
WegovyZepboundCompare

Comparing GLP-1 Medications: Questions to Ask

By TrimSoMo Editorial8 min readUpdated

Last reviewed:

Illustration of two footpaths diverging across a meadow toward the same soft hills
Key takeaway

How Wegovy (semaglutide) and Zepbound (tirzepatide) differ on mechanism, trial data, side effects, and coverage — with key questions for your prescriber.

Wegovy (semaglutide) and Zepbound (tirzepatide) are the two primary branded once-weekly medications FDA-approved for chronic weight management in the United States. While both belong to the broad family of incretin-based therapies, they are distinct molecules with different biochemical targets, different dosing ladders, and unique secondary FDA indications.

According to Google search trends, queries comparing "Wegovy vs. Zepbound," "Is Zepbound stronger than Wegovy," and "Can I switch between Wegovy and Zepbound" represent some of the highest-volume health searches today. Below is an objective, evidence-based guide to help you understand how these medications compare and prepare for an informed conversation with your prescribing clinician.

Wegovy vs. Zepbound Comparison Table

Clinical Feature Wegovy® (semaglutide injection) Zepbound® (tirzepatide injection)
Active Molecule Semaglutide Tirzepatide
Receptor Mechanism GLP-1 receptor agonist (single incretin) Dual GIP and GLP-1 receptor agonist (twin incretin)
Manufacturer Novo Nordisk Eli Lilly and Company
FDA Approval for Weight Management June 2021 November 2023
Starting Dose 0.25 mg once weekly 2.5 mg once weekly
Maintenance Dose Options 1.7 mg or 2.4 mg weekly (and 7.2 mg pen where indicated) 5 mg, 10 mg, or 15 mg weekly (2.5 mg, 7.5 mg, 12.5 mg escalation steps)
Secondary FDA Indications Reduce risk of major adverse cardiovascular events (MACE) in adults with heart disease and obesity; treatment of noncirrhotic MASH Treatment of moderate-to-severe Obstructive Sleep Apnea (OSA) in adults with obesity
Landmark Trial Programs STEP Program (STEP-1, STEP-4, SELECT) SURMOUNT Program (SURMOUNT-1, SURMOUNT-5 head-to-head)
Administration Format Single-dose pre-filled auto-injector pen Single-dose pre-filled KwikPen
Room-Temperature Stability Up to 28 days below 86°F (30°C) Up to 21 days below 86°F (30°C)
Diabetes Sister Brand Ozempic® (semaglutide) Mounjaro® (tirzepatide)

Mechanism of Action: Single vs. Dual Incretin Agonism

The foundational scientific distinction between Wegovy and Zepbound lies in how many receptor pathways each medication activates in the human body:

Wegovy (Selective GLP-1 Receptor Agonist)

Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), a peptide hormone naturally secreted by L-cells in the small intestine in response to food intake. Wegovy acts on GLP-1 receptors in both the gut and the central nervous system:

  • It slows down gastric emptying (gastric delay), which extends post-meal fullness.
  • It signals directly to satiety centers in the brain (including the hypothalamus and hindbrain), suppressing hunger signals and food cravings.
  • It stimulates glucose-dependent insulin secretion from pancreatic beta cells while dampening glucagon release.

Zepbound (Dual GIP and GLP-1 Receptor Agonist)

Tirzepatide is a first-in-class multi-incretin that mimics both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide):

  • GIP is the other major incretin hormone released by the gut following a meal.
  • By engaging both GIP and GLP-1 receptors simultaneously, Zepbound triggers a synergistic biological effect: GIP receptor activation modulates lipid metabolism in adipose tissue, enhances insulin sensitivity, and acts on hypothalamic feeding centers alongside GLP-1.
  • In clinical models, dual agonism appears to enhance metabolic flexibility and amplify satiety signaling.

(Curious how diabetes formulations fit in? Read our Ozempic vs. Wegovy breakdown).

What Clinical Trials Reported: STEP vs. SURMOUNT

Both medications demonstrated substantial clinical outcomes in large-scale randomized, double-blind, placebo-controlled trials published in The New England Journal of Medicine:

  • The STEP-1 Trial (Wegovy): Evaluated semaglutide 2.4 mg once weekly in 1,961 adults with obesity or overweight without diabetes over 68 weeks, combined with lifestyle intervention. The study documented significant reductions in body weight, waist circumference, and cardiovascular risk markers compared to placebo.
  • The SURMOUNT-1 Trial (Zepbound): Evaluated tirzepatide at weekly doses of 5 mg, 10 mg, and 15 mg in 2,539 adults with obesity or overweight over 72 weeks. The trial documented dose-dependent metabolic improvements across all three evaluation cohorts.
  • The SURMOUNT-5 Head-to-Head Trial: Specifically compared tirzepatide and semaglutide directly in a controlled clinical setting over 72 weeks, assessing comparative changes in weight reduction and metabolic endpoints.

Important clinical note: Published trial figures reflect study averages under rigorous clinical trial conditions, which included scheduled visits with registered dietitians and prescribed physical activity. Individual metabolic responses, genetic backgrounds, and adherence differ significantly; clinical trials do not guarantee personal results.

Escalation Schedules and Dosing Steps

Both medications require gradual monthly dose escalation (titration) to allow the digestive tract to adapt to delayed gastric emptying. Because the molecules and receptor potencies are completely different, milligram amounts cannot be directly compared or converted:

Wegovy Titration Ladder

  • Weeks 1–4: 0.25 mg once weekly
  • Weeks 5–8: 0.5 mg once weekly
  • Weeks 9–12: 1.0 mg once weekly
  • Weeks 13–16: 1.7 mg once weekly
  • Week 17+ (Maintenance): 2.4 mg once weekly (the recommended weight-management maintenance dose)

Zepbound Titration Ladder

  • Weeks 1–4: 2.5 mg once weekly
  • Weeks 5–8: 5.0 mg once weekly (the first potential maintenance dose)
  • Weeks 9–12: 7.5 mg once weekly (escalation step)
  • Weeks 13–16: 10.0 mg once weekly (maintenance dose)
  • Weeks 17–20: 12.5 mg once weekly (escalation step)
  • Week 21+ (Highest Labeled Step): 15.0 mg once weekly (maintenance dose)

For both medications, whether to increase to the next tier or maintain at an intermediate step is a joint decision made with your prescribing clinician based on your progress and tolerability.

Review complete schedule details in our GLP-1 dose escalation guide.

Can You Switch From Wegovy to Zepbound (or Vice Versa)?

Switching between GLP-1 medications is common in clinical practice, often triggered by insurance formulary shifts, persistent side effects, supply chain shortages, or plateaued progress.

However, you cannot simply swap equal milligrams or jump directly to the highest dose:

  1. Because tirzepatide stimulates GIP in addition to GLP-1, patients switching to Zepbound must be evaluated carefully by a physician.
  2. Even if a patient tolerated Wegovy at 2.4 mg, clinicians generally do not start Zepbound at 15 mg; doing so creates an acute risk of severe nausea, vomiting, and dehydration.
  3. Prescribers typically initiate the new medication at an introductory or intermediate titration step (e.g., 2.5 mg or 5 mg for Zepbound) to assess gastrointestinal tolerance before escalating.
  4. Combining Wegovy and Zepbound at the same time is contraindicated and strictly not advised.

If you are considering a medication change, consult your prescriber and review our guide on what to discuss when stopping or changing doses.

Side Effects and Safety Comparison

Because both therapies slow digestion and stimulate incretin receptors, their adverse reaction profiles overlap heavily. The most common adverse reactions reported in the FDA prescribing information for both products include:

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain and bloating
  • Acid reflux and belching
  • Fatigue

In clinical trials, gastrointestinal symptoms occurred predominantly during initial dose escalation steps and tended to diminish as patients acclimated to a steady maintenance dose. Tirzepatide's dual action has been reported by some clinicians to produce slightly higher frequencies of digestive discomfort at higher dose tiers (10 mg and 15 mg), while others tolerate it more smoothly than semaglutide.

Both medications carry identical FDA Boxed Warnings regarding the risk of thyroid C-cell tumors based on rodent studies. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

For practical steps on managing digestive symptoms, see our GLP-1 nausea and side-effect guide and inspect reported safety events in the FDA FAERS database.

Secondary Health Indications: Cardiovascular vs. Sleep Apnea

When deciding between the two medications, clinicians frequently look at a patient's broader comorbid conditions:

  • Choose Wegovy for Established Cardiovascular Disease: Supported by the milestone SELECT trial, Wegovy is explicitly approved by the FDA to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) in adults with overweight or obesity and established heart disease. It also carries indications in metabolic dysfunction-associated steatohepatitis (MASH).
  • Choose Zepbound for Obstructive Sleep Apnea: Zepbound received specific FDA approval for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, offering a dedicated clinical pathway for patients suffering from airway restriction and nocturnal oxygen desaturation.

Review qualifying comorbidities in our FDA label BMI criteria guide.

Insurance Coverage and Prior Authorization in 2026

Both medications carry similar wholesale acquisition list prices (typically $1,000–$1,350 per month before insurance or manufacturer discounts). However, individual insurance coverage varies dramatically depending on your employer's chosen benefits package:

  • Many insurance plans contract exclusively with either Novo Nordisk (favoring Wegovy) or Eli Lilly (favoring Zepbound) to secure negotiated rebate pricing. A plan that covers Wegovy with a $25 copay might completely exclude Zepbound, or vice versa.
  • Both medications almost universally require a comprehensive Prior Authorization (PA) demonstrating that you meet FDA BMI thresholds (BMI ≥ 30, or BMI ≥ 27 with a documented comorbidity) and have attempted structured lifestyle changes.
  • Both manufacturers offer patient copay cards for commercially insured patients whose plans cover the drug, which can significantly lower out-of-pocket costs.

If your claim is delayed or denied, consult our GLP-1 prior authorization guide.

Questions to Bring to Your Prescriber

When discussing Wegovy and Zepbound with your healthcare provider, consider raising the following targeted questions:

  1. "Does my insurance formulary prefer Wegovy or Zepbound, and what specific prior authorization criteria apply?"
  2. "Given my personal medical history—such as cardiovascular risks, fatty liver, or sleep apnea—does one mechanism offer specific advantages for me?"
  3. "If I experience persistent nausea on my current medication, would transitioning to the alternative incretin pathway be a reasonable option?"
  4. "What is our protocol for monitoring progress, tracking side effects, and adjusting the titration schedule?"

Summary & Next Steps

There is no universal "superior" choice between Wegovy and Zepbound. The best medication for you depends on your individual clinical profile, your comorbidity history, your insurance coverage, and how your digestive system tolerates each titration ladder.

To learn more about each product and connect with licensed clinicians:

Sources


General information, not medical advice. Treatment decisions should always be made in consultation with a licensed healthcare professional.

Related Guides
All guides